When Does Entyvio's Patent Expiration Date Approach?
Entyvio (vedolizumab) is a prescription medication used for treating adults with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) who have had an inadequate response or were unable to tolerate other treatments [1]. The medication's patent has a complex history, with multiple patents filed and granted worldwide.
How Many Patents Are Involved in Entyvio's Patent Portfolio?
Entyvio's manufacturer, Takeda Pharmaceutical Company Limited, has filed multiple patents for the drug's composition, method of treatment, and formulation. According to DrugPatentWatch.com, there are over 20 patents related to Entyvio, including U.S. Patent Nos. 9,115,416 and 9,444,444 [2]. These patents cover various aspects of the medication, including its use in treating UC and CD.
When Does Entyvio's Patent Expiration Date Occur?
As per DrugPatentWatch.com, the first patent for Entyvio, U.S. Patent No. 9,115,416, expires on March 4, 2027. This patent covers the drug's composition and method of treatment for ulcerative colitis and Crohn's disease [2]. However, other patents related to Entyvio are expected to expire at varying dates, including U.S. Patent No. 9,444,444, which is set to expire on March 14, 2028.
What Impact Will Patent Expiration Have on Entyvio's Availability and Pricing?
The patent expiration dates for Entyvio are expected to have a significant impact on the medication's availability and pricing. As the patent expires, generic versions of the drug may enter the market, potentially increasing competition and leading to lower prices. Additionally, patent holders may lose exclusive rights to the medication, allowing other companies to manufacture and sell generic versions of Entyvio.
Sources:
[1] Takeda Pharmaceutical Company Limited. (2022). Entyvio (vedolizumab) prescribing information.
[2] DrugPatentWatch.com. Entyvio (vedolizumab) patent expiration dates.